



03/04/02

IDS/ #131642
J 3/21/02IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Feige, et al.

Serial No.: 09/428,082

Group Art Unit No.: 1642

Filed: October 22, 1999

Examiner: S. Huff

For: Modified Peptides as Therapeutic Agents

RECEIVED

Docket No.: A-527

MAR 08 2002

TECH CENTER 1600/2900

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENTAssistant Commissioner for Patents
Washington, D.C. 20231

Sir:

As a means of complying with the duty of disclosure, applicants submit a "List of References Cited by Applicant" on a modified PTO-1449 form and provide a copy of each of the listed references for consideration by the Examiner.

The Applicants provision of these references under this and any other Information Disclosure Statement should not be deemed an admission that all such references are relevant to patentability nor are necessarily prior art in accordance with 35 U.S.C. §102.

This Information Disclosure Statement is being filed after three months of the filing date of this national application or the date of entry of the national stage as set forth in § 1.491 in an international application or after the mailing date of the first Office action on the merits, whichever event occurred last, but **before** the mailing date of either:

- (1) a final action under § 1.113 or
- (2) a notice of allowance under § 1.311,
whichever occurs first.

STATEMENT OR FEE

Accompanying this transmittal is:

A a statement as specified in 37 CFR 1.97(e):**STATEMENT****EXPRESS MAIL CERTIFICATE**

*Express Mail® mail labeling number: EL360689020US

Date of Deposit: February 28, 2002

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Sherry St. Andrew

Printed Name

S. St. Andrew

Signature

I, the person(s) signing below state:

- that each item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. 37 CFR 1.97(e)(1).

OR

- that no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the statement after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the information disclosure statement. 37 CFR 1.97(e)(2).

OR

- B. the fee set forth in 37 CFR 1.17(p) for submission of an information disclosure statement under § 1.97(c). (\$180.00).

Applicants request consideration of this information and passage of the application to issue.

FEE PAYMENT

Please charge Deposit Account No. 01-0519 in the amount of \$180.00 (37 CFR 1.97(c)). An original and one copy are enclosed.

The Commissioner is hereby authorized to charge any additional fees which may be required or credit any overpayment to Deposit Account No. 01-0519.

Respectfully submitted,



Timothy J. Gail

Attorney for Applicants

Registration No.: 33,111

Phone: (805) 447-2688

Date: February 28, 2002

Please send all future correspondence to:
US Patent Operations/ TJG
Dept. 4300, M/S 27-4-A
AMGEN INC.
One Amgen Center Drive
Thousand Oaks, California 91320-1799